Documentaries, videos and podcasts
July 14, 2021
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
July 5, 2021
Infectious Diseases of Poverty
Various modalities of vaccines against coronavirus disease 2019 (COVID-19), based on different platforms and immunization procedures, have been successively approved for marketing worldwide. A comprehensive review for clinical trials assessing the safety of COVID-19 vaccines is urgently needed to make an accurate judgment for mass vaccination. A systematic review and meta-analysis was conducted to determine the safety of COVID-19 vaccine candidates in randomized controlled trials (RCTs). Data search was performed in PubMed, Embase, Cochrane library, Scopus, Web of Science, and MedRxiv. Included articles were limited to RCTs on COVID-19 vaccines. A total of 73,633 subjects from 14 articles were included to compare the risks of adverse events following immunization (AEFI) after vaccinating different COVID-19 vaccines. Pooled risk ratios (RR) of total AEFI for inactivated vaccine, viral-vectored vaccine, and mRNA vaccine were 1.34 [95% confidence interval (CI) 1.11-1.61, P < 0.001], 1.65 (95% CI 1.31-2.07, P < 0.001), and 2.01 (95% CI 1.78-2.26, P < 0.001), respectively. No significant differences on local and systemic AEFI were found between the first dose and second dose. In addition, people aged ≤ 55 years were at significantly higher risk of AEFI than people aged ≥ 56 years, with a pooled RR of 1.25 (95% CI 1.15-1.35, P < 0.001). The safety and tolerance of current COVID-19 vaccine candidates are acceptable for mass vaccination, with inactivated COVID-19 vaccines candidates having the lowest reported AEFI. Long-term surveillance of vaccine safety is required, especially among elderly people with underlying medical conditions.
Eli Lilly and Company
June 26, 2021
/PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes after 40 weeks...
June 25, 2021
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a...
June 23, 2021
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Aimovig®...
Institute for Economics & Peace (IEP)
June 17, 2021
/PRNewswire/ -- Today marks the launch of the 15th edition of the Global Peace Index from the international think-tank the Institute for Economics & Peace...
June 10, 2021
/PRNewswire/ -- A AbbVie (NYSE: ABBV) anunciou que o periódico científico The Lancet publicou análise inicial dos estudos globais -pivotais de Fase 3 - Measure...
June 3, 2021
/PRNewswire/ -- BizVibe has identified changes in safety standards as a major trend for the specialty trade contractors industry. Regulations such as those...
June 2, 2021
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results of an analysis from the Phase 3 SELECT-PsA 2 clinical trial, showing that continuous treatment with...
June 2, 2021
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new analyses to be presented at the EULAR 2021 Virtual Congress showing patients with moderate to severe...
May 23, 2021
Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn's Disease - read this article along with other careers information, tips and advice on BioSpace
The Janssen Pharmaceutical Companies of Johnson & Johnson
May 23, 2021
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn's...
May 19, 2021
- No estudo SELECT- PsA 1, upadacitinibe (15 mg e 30 mg) melhorou os principais sintomas articulares e cutâneos em até 24 semanas de tratamento, incluindo...
May 18, 2021
/PRNewswire/ -- Highmark Health announced today it has earned the WELL Health-Safety Rating from the International WELL Building Institute (IWBI) for six...
May 17, 2021
Professor Akimichi Morita, Vice Director of Nagoya City University Hospital, will lead RepliCel's Skin Rejuvenation Clinical Testing in Japan
May 10, 2021
Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA - read this article along with other careers information, tips and advice on BioSpace
May 3, 2021
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan) - read this article along with other careers information, tips and advice on BioSpace
April 30, 2021
As Etsy's sales boomed during the pandemic, rogue sellers ran wild. Among the listings: Dead pets, uranium, poisonous plants and porn.
Pye-Barker Fire & Safety
April 23, 2021
/PRNewswire/ -- Pye-Barker Fire & Safety ("Pye-Barker Fire") is proud to announce the acquisition of T & S Fire and Security, Inc. ("T & S Fire"), located in...
April 20, 2021
Under the third phase of the vaccination drive commencing next month, manufacturers would be free to supply 50 percent doses to state governments as well as in the open market, for which they will have to make an advance declaration of the price, the government said in a statement.